Royalty Pharma Files 8-K on Material Agreements
Ticker: RPRX · Form: 8-K · Filed: Dec 31, 2024 · CIK: 1802768
| Field | Detail |
|---|---|
| Company | Royalty Pharma PLC (RPRX) |
| Form Type | 8-K |
| Filed Date | Dec 31, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-reporting, corporate-action
TL;DR
Royalty Pharma filed an 8-K on 12/31/24 covering material agreements and financial updates.
AI Summary
Royalty Pharma plc filed an 8-K on December 31, 2024, reporting on a material definitive agreement, amendments to its articles of incorporation or bylaws, and financial statements. The filing details the company's principal executive offices located at 110 East 59th Street, New York, NY 10022, and its telephone number is (212) 883-0200. The company is incorporated in England and Wales and operates in the Pharmaceutical Preparations industry.
Why It Matters
This filing provides updates on significant corporate actions and financial reporting for Royalty Pharma plc, which could impact investors' understanding of the company's current status and future direction.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of material agreements and financial statements, not indicating any immediate operational or financial distress.
Key Players & Entities
- Royalty Pharma plc (company) — Registrant
- December 31, 2024 (date) — Date of Report
- 110 East 59th Street (address) — Principal executive offices
- New York, New York (location) — Principal executive offices city and state
- 10022 (zip_code) — Principal executive offices zip code
- (212) 883-0200 (phone_number) — Registrant's telephone number
- England and Wales (location) — Jurisdiction of incorporation
FAQ
What specific material definitive agreement was entered into by Royalty Pharma plc?
The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in this excerpt.
What amendments were made to Royalty Pharma plc's articles of incorporation or bylaws?
The filing notes amendments to articles of incorporation or bylaws, but the specific changes are not detailed in this provided text.
What financial statements are included in this 8-K filing?
The filing states that financial statements are included, but the specific statements are not detailed in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on December 31, 2024.
What is Royalty Pharma plc's Standard Industrial Classification (SIC) code?
Royalty Pharma plc's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 616 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-12-31 16:05:31
Key Financial Figures
- $0.0001 — red Class A Ordinary Shares, par value $0.0001 per share RPRX The Nasdaq Stock Mar
Filing Documents
- d900232d8k.htm (8-K) — 26KB
- d900232dex31.htm (EX-3.1) — 462KB
- d900232dex101.htm (EX-10.1) — 268KB
- g900232g1228091241288.jpg (GRAPHIC) — 4KB
- 0001193125-24-287172.txt ( ) — 989KB
- rprx-20241231.xsd (EX-101.SCH) — 3KB
- rprx-20241231_lab.xml (EX-101.LAB) — 18KB
- rprx-20241231_pre.xml (EX-101.PRE) — 11KB
- d900232d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits 3.1 Articles of Association of RP Holdings 10.1 Exchange Agreement dated December 31, 2024, among the Company, RP Holdings, RPI US Partners 2019, LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP, RPI US Feeder 2019, LP, RPI International Feeder 2019, LP, RPI EPA Holdings, LP and RPI EPA Vehicle LLC 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ROYALTY PHARMA PLC Date: December 31, 2024 By: /s/ Terrance Coyne Terrance Coyne Chief Financial Officer